Faisal Zain is a leading voice in the evolution of medical technology, bringing years of expertise in the manufacturing of sophisticated diagnostic and treatment devices. His work sits at the intersection of traditional medical engineering and the rapid integration of artificial intelligence, where he focuses on transforming raw innovation into safe, clinical-grade tools. In this discussion, we explore the collaborative efforts between technology giants and premier health systems to build a robust evidence base for AI. From the precision of radiotherapy planning to the complexities of ethical data management, the conversation highlights how a phased, responsible approach is reshaping the future of patient care.
Large language models are now being optimized for diagnostic reasoning and clinical consultations. How do these systems balance the need for conversational fluidity with the strict accuracy required for patient safety?
The development of systems like the Articulate Medical Intelligence Explorer, or AMIE, represents a fundamental shift in how we approach conversational AI in a clinical setting. To achieve this balance, research leads like Alan Karthikesalingam and Vivek Natarajan have focused on training these models across multiple dimensions that reflect the true quality of a real-world consultation. We aren’t just looking at whether the AI sounds human; we are evaluating it from the perspective of both the clinician’s diagnostic accuracy and the patient’s experience of being heard. This rigorous evaluation includes testing the AI’s ability to pass medical licensing exams, which it has already done successfully, proving that the underlying logic is sound. By using actors to simulate high-stakes scenarios like heart failure or breast cancer, we can refine the AI’s reasoning in a safe environment before it ever interacts with a vulnerable patient in a live clinic.
The shift from laboratory testing to real-world virtual care workflows is a massive undertaking. What can you tell us about the significance of nationwide randomized controlled studies in validating conversational AI?
Moving AI out of a “safe testing harness” and into the chaotic reality of virtual care requires a level of evidence that only randomized controlled studies can provide. For instance, the upcoming 2026 collaboration with Included Health is designed to specifically measure the impact of conversational AI on real-world virtual care workflows across the entire country. As Mike Schaekermann and Cameron Chen have noted, this research builds on a foundation of using AI for personalized health insights and navigating complex information. We have already seen the potential in smaller scales, such as a study with Harvard University where 120 actual patients chatted with an AI under the watchful eyes of standby physicians. These large-scale studies are essential because they move us past the “hype” phase and provide the hard data needed to show exactly where these tools improve outcomes and where they might still need human intervention.
Specialized fields like oncology often require extreme precision. How is AI currently being utilized to improve the efficiency and standardization of treatments like radiotherapy?
Radiotherapy planning is an incredibly labor-intensive process where even a millimeter of error can have significant consequences, but AI is proving to be a game-changer in this arena. In our work with the Mayo Clinic, we have seen deep-learning models used to create contours for patients with head and neck cancers that are ready for clinical use with minor or no revisions 90% of the time. This is a staggering improvement when you consider that manual contouring by highly trained professionals only met that same standard 53% of the time in the same study. Beyond the increase in standardization, the sheer speed of the technology is transformative, reducing the overall contouring and process time by 76%. This allows oncology teams to move much more quickly from diagnosis to the start of treatment, which is often a critical factor in a patient’s prognosis.
Sharing sensitive clinical data with tech companies often raises privacy concerns. How are organizations structuring their partnerships to ensure data remains secure while still enabling innovation?
The partnership between Google and Mayo Clinic, which began as a 10-year commitment in 2019, offers a brilliant framework for how to handle the ethical utilization of clinical data. Instead of moving sensitive information to the tech company, they use a model where the algorithms are permitted into a secure enclave, meaning the data never actually leaves the home institution. This approach allows for the generation of knowledge and the training of models while addressing the most pressing privacy and cybersecurity concerns head-on. Furthermore, the use of de-identified clinical data within the Mayo Clinic Platform ensures that individual patient identities are protected while still providing the large datasets needed for algorithmic development. To keep the community’s trust, the 2021 establishment of the Health Data and Technology Advisory Board ensures that a diverse group of patients can provide their perspectives on how this technology impacts them personally and socially.
With Microsoft and Amazon also entering the arena with specialized healthcare AI, how do you see the competition among tech giants benefiting the average healthcare provider?
The entrance of companies like Microsoft and Amazon into the clinical space is accelerating the delivery of high-quality, personalized care by making advanced tools accessible to a broader range of providers. Microsoft’s move to make Mayo-owned models available via Azure Foundry APIs means that world-class clinical expertise can be integrated into hospital systems globally through the cloud. On the administrative side, Amazon Connect Health is tackling the burnout crisis by using agentic AI to handle repetitive tasks like patient identity verification and appointment management. We have seen one health system successfully shift 630 hours per week from these manual verification tasks to direct patient assistance, which drastically improves the human experience of healthcare. Additionally, “pathway assistants” powered by models like Gemini are helping clinicians at the bedside by instantly surfacing information that was previously buried in thick binders or static PDFs, saving precious minutes during vital moments of care.
What is your forecast for the future of AI integration in global healthcare systems?
I forecast that we are entering an era of “evidence-based implementation” where the focus shifts from what AI could do to what it actually does in the hands of a doctor. We will see a phased and gradual rollout of these technologies, led by chief health officers like Michael Howell, who emphasize the importance of building a robust evidence base before widespread adoption. Within the next few years, AI will likely become an invisible but essential part of the clinical infrastructure, much like electronic health records, but with the added benefit of being a proactive partner in diagnostic reasoning. The most successful systems will be those that prioritize safety and responsibility, ensuring that every algorithmic advancement is backed by rigorous research and a commitment to enhancing the human connection between provider and patient. Ultimately, the technology will not replace the physician, but it will liberate them from the administrative and repetitive burdens that currently hinder the delivery of care.
